Preview Mode Links will not work in preview mode

This Week in Cardiology

Mar 22, 2024

p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Denmark Notes

II. FDA approval of Semaglutide

FDA Approves Semaglutide for Cardiovascular Risk Reduction

  • Select Trial

III. PPG Monitor Accuracy

  • Research Letter

IV. AAD and Bradycardia

Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF

  • JACC paper on AAD Adverse Effects

V. Finding Signals in RCTs

  • JAMA paper on Treatment Effects of Oxygen Targets
  • DANISH trial
  • LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact